Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

18 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

GSK AVA100193 Rosiglitazone in Alzheimer´s Disease - Pharmacogenetic and Pharmacogenomic Research - Pharmacogenetic and Pharmacogenomic Research

- 25-09-17 - 1 Formulier, 1 Itemgroep, 10 Data-elementen, 1 Taal
Itemgroep: PGx-Pharmacogenetic/PGm-Transcriptomic/PGM-Proteomic Research
A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease.

GSK Ropinirole in Subjects with Restless Legs Syndrome 101468/191 Week 12 Day (Form 16)

- 01-09-17 - 1 Formulier, 6 Itemgroepen, 17 Data-elementen, 1 Taal
Itemgroepen: General Information, Investigational Product Record since last visit, RSL Rating Scale, Vital Signs, Laboratory Evaluation, Pregnancy Dipstick
Study ID: 101468/191 Clinical Study ID: SKF-101468/191 Study Title:A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication: Restless Legs Syndrome

GSK Ropinirole in Subjects with Restless Legs Syndrome 101468/191 Baseline (Form 2)

- 31-08-17 - 1 Formulier, 13 Itemgroepen, 59 Data-elementen, 1 Taal
Itemgroepen: General Information, Orthostatic Vital Signs, Baseline PLMI, Polysomnography, Baseline Inclusion Criteria, Baseline Exclusion Criteria, RLS rating scales, Vital signs, Concomitant Medication, Medical Procedures, Baseline Signs and Symptoms, Baseline Employment Status, Ramos Randomization and dispensing
Study ID: 101468/191 Clinical Study ID: SKF-101468/191 Study Title:A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication: Restless Legs Syndrome

GSK Study: Evaluation of safety and efficacy of VarilrixTM and of Combined Measles-Mumps-Rubella-Varicella Vaccine NCT00226499 - Visit 3 and Guardians contact for rash

- 20-08-17 - 1 Formulier, 7 Itemgroepen, 25 Data-elementen, 1 Taal
Itemgroepen: Check for study continuation, Laboratory tests, Household exposure, Household exposure number, Varicella or zoster, Parents/Guardians contact for rash, Parents/Guardians contact for rash
GSK Study: Evaluation of safety and efficacy of VarilrixTM and of Combined Measles-Mumps-Rubella-Varicella Vaccine NCT00226499 - Visit 3 - Day 84 and Parents/ Guardians contact for rash Study ID: 100388 Clinical Study ID: 100388 Study Title: Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00226499 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Varicella Vaccine Trade Name: BIO OKAH; Varilrix Study Indication: Varicella

GSK study: Ropinirole in RLS patients 101468/243 - Week 52

- 30-07-17 - 1 Formulier, 10 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Study medication record since last visit, RLS Rating scale, Vital signs, Laboratory test, Urine dipstick, Pregnancy dipstick, Medical procedures, Concomitant Medication, Adverse reaction, Clinical global impression
Part 1 of Module 12: Wk 52, Follow-Up & Study Conc 101468/243 Study ID: 101468/243 Clinical Study ID: 101468/243 Study Title: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome

Laboratory of molecular hematology and oncology molecular genetic finding University Hospital Cologne

- 26-03-17 - 1 Formulier, 1 Itemgroep, 14 Data-elementen, 1 Taal
Itemgroep: molecular genetic finding
Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name: MED1 LMHO_Mole_BE_sub

Cumulative Laboratory Findings University Hospital Cologne

- 25-03-17 - 1 Formulier, 1 Itemgroep, 5 Data-elementen, 1 Taal
Itemgroep: Cumulative Laboratory Findings
Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name: LAWP_KumulativbefundwerteKUK1

Laboratory Findings University Hospital Cologne

- 25-03-17 - 1 Formulier, 1 Itemgroep, 19 Data-elementen, 1 Taal
Itemgroep: laboratory findings
Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name:

Visit 9 Follow-up Laboratory Test: Central Lab [LB_1] NCT01117584

- 04-02-17 - 1 Formulier, 1 Itemgroep, 3 Data-elementen, 1 Taal
Itemgroep: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Visit 8 Follow-Up Laboratory Test: Central Lab [LB_1] NCT01117584 - Visit 8 Follow-Up Laboratory Test: Central Lab [LB_1] NCT01117584

- 04-02-17 - 1 Formulier, 1 Itemgroep, 3 Data-elementen, 1 Taal
Itemgroep: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Visit 2 Baseline Laboratory Test: Central Lab [LB_1] NCT01117584

- 28-01-17 - 1 Formulier, 1 Itemgroep, 3 Data-elementen, 1 Taal
Itemgroep: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Visit 3 Laboratory Test: Central Lab [LB_1] NCT01117584

- 28-01-17 - 1 Formulier, 1 Itemgroep, 3 Data-elementen, 1 Taal
Itemgroep: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial